RGNX Stock Cash Flow Statements

REGENXBIO Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

REGENXBIO Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31

cash flows from operating activities
net income	-70,871,000	6,083,000	-51,186,000	-59,597,000	-52,989,000	-63,330,000	-62,889,000	-61,868,000	-72,061,000	-66,676,000	-59,935,000	-75,484,000	-68,179,000	-76,723,000	294,023,000	-58,405,000	-57,639,000	-50,139,000	-46,241,000	8,791,000	-33,762,000	-40,038,000	-26,464,000	-34,584,000	-1,457,000	-32,228,000	4,306,000	-19,202,000	10,594,000	104,239,000	-15,997,000	-20,706,000	-14,473,000	-21,993,000	-19,608,000	-18,154,000	-14,437,000	-10,768,000	-5,176,000
adjustments to reconcile net income to net cash from operating activities
stock-based compensation expense	8,653,000	8,537,000	9,542,000	9,884,000	9,435,000	9,602,000	8,338,000	10,219,000	10,504,000	11,206,000	9,408,000	10,245,000	10,335,000	10,800,000	9,162,000	9,734,000	9,992,000	9,920,000	7,581,000	8,035,000	8,316,000	8,017,000	6,875,000	7,162,000	7,099,000	5,718,000	4,886,000	4,483,000	3,981,000	3,291,000	2,796,000	2,735,000	2,483,000	2,591,000	2,000,000	1,829,000	1,656,000	1,546,000	862,000
depreciation and amortization	3,905,000	3,955,000	4,023,000	3,961,000	4,051,000	4,180,000	4,335,000	4,372,000	4,435,000	4,178,000	4,126,000	3,549,000	2,643,000	2,591,000	2,606,000	2,828,000	2,201,000	1,929,000	2,105,000	2,176,000	2,132,000	1,994,000	1,923,000	1,866,000	1,749,000	1,614,000	1,311,000	941,000	896,000	834,000	723,000	706,000	703,000	554,000	280,000	160,000	56,000	48,000	37,000
net accretion of discounts on marketable debt securities	-1,356,000	-1,071,000
impairment of long-lived assets			0	0	0	2,101,000
non-cash interest expense	2,767,000	-277,000	5,689,000	439,000	-715,000	688,000	155,000	667,000	-662,000	-574,000	-630,000	-107,000	820,000	54,000	-15,135,000	6,709,000	6,366,000	6,702,000
other non-cash adjustments	22,000	-10,000	1,384,000	11,000	0	-71,000	154,000	220,000	-3,000	-52,000	33,000	232,000	351,000	-43,000	130,000	166,000	-63,000	-154,000	-100,000	-110,000	348,000	25,000	-89,000	-85,000	115,000	327,000	2,000	-1,000	3,000	10,000	34,000	-1,000	-1,000	41,000
changes in operating assets and liabilities
accounts receivable	-2,362,000	1,572,000	8,133,000	-710,000	-6,893,000	9,177,000	3,369,000	-6,542,000	-2,387,000	9,495,000	4,844,000	5,006,000	-10,717,000	5,689,000	22,004,000	-6,402,000	-3,102,000	1,618,000	79,544,000	-86,731,000	3,033,000	-5,744,000	2,077,000	-9,280,000	-2,010,000	591,000	-23,789,000	-1,893,000	60,293,000	-51,414,000	411,000	-832,000	179,000	803,000	-386,000	106,000	1,240,000	113,000
prepaid expenses	318,000	-2,027,000	1,935,000	-981,000	3,569,000	930,000	-1,959,000	2,551,000	409,000	-1,621,000	924,000	1,421,000	2,297,000	210,000	-351,000	-5,309,000	747,000	-3,334,000	5,607,000	-6,363,000	-2,327,000	-947,000	445,000	-884,000	256,000	-790,000	574,000	-2,618,000	977,000	667,000	-2,109,000	-793,000	-589,000	-68,000	396,000	-691,000	-291,000	-169,000	380,000
other current assets	-3,353,000	-2,240,000	9,315,000	166,000	3,856,000	-6,826,000	3,027,000	-727,000	805,000	-13,651,000	-2,504,000	1,316,000	-1,607,000	3,042,000	-4,007,000	-200,000	-2,234,000	-873,000	5,339,000	74,000	-239,000	-2,833,000	-1,785,000	-133,000	1,714,000	-295,000	1,003,000	-2,487,000	-139,000	-446,000	-22,000	-138,000	-330,000	88,000	990,000	-563,000	-137,000	-449,000	-724,000
operating lease right-of-use assets	1,668,000	1,638,000	1,610,000	1,575,000	1,483,000	1,528,000	1,516,000	1,439,000	1,416,000	1,390,000	1,367,000	1,066,000	1,038,000	979,000	1,086,000	1,298,000	1,250,000	1,232,000	1,233,000	543,000	740,000	703,000	719,000	556,000	583,000	573,000
other assets	1,108,000	1,013,000	332,000	-1,386,000	1,271,000	590,000	-138,000	-836,000	4,457,000	-1,893,000	1,953,000	-2,445,000	2,624,000	-2,101,000	2,130,000	-1,989,000	1,376,000	-3,789,000	-919,000	-37,000	-350,000	1,705,000	-544,000	-800,000	-1,376,000	26,000	-665,000	-136,000	-631,000	-21,000	-26,000	-23,000	-96,000	10,000	-68,000	27,000	-43,000	-55,000	-40,000
accounts payable	2,534,000	-3,651,000	3,038,000	3,124,000	-14,915,000	8,461,000	1,220,000	10,097,000	-11,005,000	-3,103,000	1,907,000	7,356,000	-7,228,000	16,755,000	-8,807,000	7,350,000	-1,125,000	278,000	-6,034,000	5,829,000	1,015,000	3,063,000	-3,811,000	3,565,000	1,458,000	316,000	-374,000	496,000	-817,000	477,000	1,479,000	-1,581,000	255,000	2,468,000	-3,409,000	2,665,000	1,112,000	-182,000	273,000
accrued expenses and other current liabilities	11,922,000	-14,489,000	-10,676,000	6,103,000	9,526,000	-17,077,000	3,998,000	-5,047,000	18,944,000	-15,443,000	2,625,000	-2,648,000	880,000	-26,473,000	29,435,000	6,353,000	4,664,000	-10,544,000	-1,000,000	16,966,000	5,247,000	-3,813,000	4,892,000	2,947,000	1,975,000	-2,932,000	4,144,000	872,000	2,076,000	490,000	-1,552,000	3,480,000	1,889,000	-1,920,000	-718,000	1,609,000	1,772,000	1,210,000
deferred revenue	-2,104,000	39,770,000	-29,000	123,000	8,000	-135,000	-294,000	-6,000	-779,000	-433,000	-3,989,000	-648,000											0	0			3,333,000	0
operating lease liabilities	-2,177,000	-2,219,000	-2,062,000	-1,998,000	-1,982,000	-2,041,000	-1,637,000	-1,659,000	-1,841,000	-1,504,000	-494,000	-597,000	-461,000	1,008,000	1,224,000	357,000	6,248,000	4,244,000	4,361,000	-1,025,000	-346,000	-851,000	-423,000	-661,000	-579,000	-592,000
other liabilities	-16,000	-2,955,000	61,000	53,000	41,000	-2,764,000	121,000	107,000	106,000	-2,849,000	168,000	161,000	846,000	6,935,000	291,000	-30,000	66,000	-38,000	-21,000	-37,000	-10,000	-1,156,000	-16,000	-25,000	162,000	-644,000	1,814,000	-29,000	-1,056,000	957,000
net cash from operating activities	-49,342,000	33,629,000	-31,624,000	-40,549,000	-45,497,000	-55,455,000	-40,760,000	-49,407,000	-47,322,000	-80,918,000	-39,372,000	-50,456,000	-61,749,000	-55,911,000	326,237,000	-36,359,000	-29,872,000	-41,131,000	39,468,000	-36,460,000	-21,496,000	-35,573,000	-25,506,000	-29,153,000	-23,749,000	-29,297,000	-4,140,000	-19,557,000	70,211,000	58,134,000	-13,826,000	-17,136,000	-9,549,000	-17,481,000	-20,423,000	-11,818,000	-8,430,000	-7,887,000	-4,443,000
capex	-391,000	-1,024,000	-1,079,000	-326,000	-474,000	-557,000	-1,126,000	-1,439,000	-2,577,000	-4,818,000	-5,470,000	-5,050,000	-9,237,000	-10,967,000	-14,614,000	-18,698,000	-20,109,000	-27,238,000	-6,123,000	-6,072,000	-3,278,000	-4,630,000	-1,031,000	-2,679,000	-5,555,000	-2,455,000	-4,889,000	-3,372,000	-2,673,000	-2,344,000	-2,101,000	-450,000	-1,680,000	-2,929,000	-5,070,000	-1,346,000	-558,000	6,000	-128,000
free cash flows	-49,733,000	32,605,000	-32,703,000	-40,875,000	-45,971,000	-56,012,000	-41,886,000	-50,846,000	-49,899,000	-85,736,000	-44,842,000	-55,506,000	-70,986,000	-66,878,000	311,623,000	-55,057,000	-49,981,000	-68,369,000	33,345,000	-42,532,000	-24,774,000	-40,203,000	-26,537,000	-31,832,000	-29,304,000	-31,752,000	-9,029,000	-22,929,000	67,538,000	55,790,000	-15,927,000	-17,586,000	-11,229,000	-20,410,000	-25,493,000	-13,164,000	-8,988,000	-7,881,000	-4,571,000
cash flows from investing activities
purchases of marketable debt securities	-211,141,000	-19,157,000	-16,223,000	-36,198,000	-82,528,000	-55,190,000	-18,639,000	-18,130,000			-11,965,000	-14,550,000	-28,874,000	-129,486,000	-235,473,000	-20,680,000	-8,364,000	-233,627,000	-43,667,000	-8,709,000	-39,973,000	-30,692,000
maturities of marketable debt securities	71,096,000	64,924,000	51,792,000	86,782,000	82,734,000	68,930,000	53,739,000	56,251,000	107,590,000	67,912,000	44,135,000	72,119,000	37,030,000	49,862,000	33,700,000	49,916,000	36,005,000	50,465,000	43,586,000	43,529,000	85,446,000	60,907,000
purchases of property and equipment	-391,000	-1,024,000	-1,079,000	-326,000	-474,000	-557,000	-1,126,000	-1,439,000	-2,577,000	-4,818,000	-5,470,000	-5,050,000	-9,237,000	-10,967,000	-14,614,000	-18,698,000	-19,842,000	-31,021,000	-12,889,000	-6,072,000	-3,278,000	-4,630,000	-1,031,000	-2,679,000	-5,555,000	-2,455,000	-4,889,000	-3,372,000	-2,673,000	-2,344,000	-2,101,000	-450,000	-1,680,000	-2,929,000	-4,435,000	-2,223,000	-1,075,000	-416,000	-128,000
net cash from investing activities	-140,436,000	44,743,000	40,273,000	50,258,000	-268,000	13,183,000	33,974,000	38,657,000	55,218,000	63,094,000	26,700,000	53,043,000	-1,081,000	-90,591,000	-216,359,000	16,101,000	7,799,000	-214,183,000	11,570,000	33,998,000	44,482,000	32,709,000	14,154,000	52,272,000	21,672,000	5,461,000		-136,723,000	-38,367,000	-37,086,000	-1,143,000	18,765,000	-25,575,000	3,163,000	17,210,000	9,799,000	2,893,000	-10,739,000	-144,341,000
cash flows from financing activities
proceeds from exercise of stock options	78,000	150,000	38,000	398,000	192,000	884,000	209,000	92,000	749,000	471,000	43,000	917,000	1,507,000	337,000	985,000	1,729,000	275,000	1,292,000	1,376,000	268,000	1,825,000	2,154,000	1,549,000	384,000	1,367,000	3,762,000	5,448,000	2,052,000	3,175,000	3,824,000	1,741,000	423,000	168,000	161,000	5,000	44,000	109,000	21,000	7,000
taxes paid related to net settlement of stock-based awards	0	-510,000	0	0	0	-910,000	0	0	0	-419,000	0	0	0	-284,000
proceeds from issuance of common stock under employee stock purchase plan	0	307,000	0	780,000	0	411,000	0	1,243,000	0	583,000	0	1,120,000	0	622,000	0	1,141,000	0	627,000	0	1,192,000	0	607,000	0	949,000	0	365,000	-3,000	508,000	0	342,000	0	409,000	0	147,000
proceeds from public offering of common stock and pre-funded warrants, net of issuance costs			0
offering expenses related to at-the-market offering programs	-112,000	-147,000
proceeds from issuance of royalty bond and warrants, net of transaction costs
repayments under royalty monetization liabilities, net of interest
net cash from financing activities	139,232,000	-5,794,000	-7,740,000	-10,857,000	-9,445,000	120,725,000	-11,962,000	-4,805,000	-9,162,000	-9,037,000	-8,920,000	-5,417,000	-7,669,000	-6,834,000	7,644,000	-8,427,000	-12,337,000	208,370,000	194,168,000	1,460,000	1,825,000	2,761,000	1,549,000	1,333,000	1,367,000	4,127,000	5,288,000	191,814,000	3,175,000	4,166,000	1,741,000	606,000	10,728,000	71,523,000	-55,000	44,000	109,000	21,000	-2,424,000
net increase in cash and cash equivalents and restricted cash	-50,546,000	72,578,000	909,000	-1,148,000	-55,210,000	78,453,000									117,522,000	-28,685,000			245,206,000	-1,002,000			-9,803,000	24,452,000	-710,000	-19,709,000	-66,034,000	35,534,000	35,019,000	25,214,000
cash and cash equivalents and restricted cash
beginning of period	0	59,556,000	0	0	0	36,552,000	0	0	0	98,982,000	0	0	0	347,239,000	0	0	0	339,756,000	0	0	0	70,844,000	0	0	0	76,614,000	0	0	0	46,881,000	0	0	0	24,840,000	0	0	0	54,116,000	0
end of period	-50,546,000	132,134,000	909,000	-1,148,000	-55,210,000	115,005,000	-18,748,000	-15,555,000	-1,266,000	72,121,000	-21,592,000	-2,830,000	-70,499,000	193,903,000	117,522,000	-28,685,000	-34,410,000	292,812,000	245,206,000	-1,002,000	24,811,000	70,741,000	-9,803,000	24,452,000	-710,000	56,905,000	-66,034,000	35,534,000	35,019,000	72,095,000	-13,228,000	2,235,000	-24,396,000	82,045,000	-3,268,000	-1,975,000	-5,428,000	35,511,000	-151,208,000
repayments under liability related to sale of future royalties, net of imputed interest		-5,594,000	-7,613,000	-11,730,000	-9,285,000	-11,226,000	-11,752,000	-10,963,000	-9,911,000	-9,672,000	-8,963,000	-7,454,000	-9,176,000	-7,509,000
benefit from credit losses															-8,101,000	4,967,000	0	565,000	0
net amortization of premiums (accretion of discounts) on marketable debt securities			-1,117,000	-1,316,000	-1,243,000	-468,000
net realized gain on investments
sales of equity securities							0				0				28,000
proceeds from private placement of common stock, net of issuance costs							0
supplemental cash flow information
cash paid (received) for income taxes
cash paid for imputed interest under liability related to sale of future royalties
offering expenses related to at-the-market offering program				-20,000	-103,000	-35,000	-419,000
proceeds from public offering of common stock and pre-funded warrants, net of underwriting discounts and commissions					0	131,601,000
issuance costs for public offering of common stock and pre-funded warrants
net amortization of premiums on marketable debt securities							-242,000	-133,000	380,000	682,000	903,000	1,131,000	1,218,000	1,460,000		1,506,000
proceeds from public offering of common stock, net of underwriting discounts and commissions															0	0	0	216,438,000													0	0	10,695,000	71,299,000
issuance costs for public offering of common stock															0	0															0	-226,000	-135,000	-84,000
transaction costs for sale of future royalties															0	0	0	-265,000
net gain on investments											0	7,000
imputed interest income from licensing								-56,000	-40,000	-70,000	-78,000	-17,000	-153,000	-94,000	-19,000	-110,000	-202,000	-29,000	-130,000	-133,000	-1,052,000	-848,000	-860,000	-716,000	-762,000	-613,000	-584,000	-109,000	-6,898,000	-1,355,000
net decrease in cash and cash equivalents and restricted cash								-15,555,000	-1,266,000	-26,861,000		-2,830,000	-70,499,000	-153,336,000				-46,944,000				-103,000
net income on investments
sales of marketable debt securities																			0	0
proceeds from sale of future royalties
net gains on investments
taxes paid related to net settlement of stock options
supplemental disclosures of non-cash investing and financing activities
increase in accounts payable and accrued liabilities related to purchases of property and equipment
non-cash additions to property and equipment through tenant improvement allowance																			46,000
non-cash consideration received for licenses granted																			0	0											0
transaction costs for sale of future royalties in accounts payable and other current liabilities
proceeds due to company from sales of non-marketable equity securities															-46,000
net incomees (gains) on investments
repayments under liability related to sale of future royalties																-11,297,000	-12,484,000	-9,471,000
net additions to property and equipment through accounts payable and accrued expenses
net realized and unrealized losses (gains) on marketable securities																	0	-7,000	-13,125,000
sales of marketable equity securities																			24,540,000	5,250,000	0	7,124,000
additions to property and equipment through accounts payable and accrued expenses																	-267,000	3,783,000	6,766,000
net amortization of premiums on marketable securities																		1,288,000
issuance costs for public offerings of common stock																		-251,000
net amortization of premiums (accretion of discounts) on marketable securities
deferred rent																											9,000	-60,000	-8,000	27,000	32,000	-29,000	-45,000	-44,000	-25,000	701,000	148,000	453,000	48,000
proceeds from public offerings of common stock, net of underwriting discounts and commissions
assets acquired under financing lease obligation
transaction costs for sale of future royalties in accounts payable and accrued expenses
net amortization of premiums and accretion of discounts on marketable debt securities																					166,000	39,000	-111,000	-297,000	-420,000	-368,000	-134,000	171,000	340,000	378,000	405,000	465,000	476,000	469,000	502,000	515,000	516,000	471,000
net realized gains on sales and maturities of marketable securities																					10,000	-7,085,000
unrealized losses (gains) on marketable equity securities
unrealized losses on marketable equity securities																						12,196,000
net realized losses (gains) on sales and maturities of marketable securities																							-5,970,000
unrealized gains on marketable equity securities																							-2,364,000	2,236,000
purchases of marketable securities																							-62,810,000	-21,806,000	-26,870,000	-79,249,000	-125,932,000	-180,816,000	-84,814,000	-54,267,000	-22,041,000	0	-41,405,000	-5,188,000	-12,810,000	-1,000	-11,832,000	-20,429,000	-144,213,000
maturities of marketable securities																							71,975,000	76,757,000	54,097,000	87,165,000	63,639,000	47,465,000	49,120,000	19,525,000	22,999,000	19,215,000	17,510,000	10,500,000	34,455,000	12,000,000	16,025,000	10,106,000
sales of marketable securities																															0	0	0	780,000	0
cash paid for income taxes
purchases of property and equipment in accounts payable and accrued expenses																																			-635,000	877,000	517,000	422,000
issuance costs for public offerings of common stock in accounts payable and accrued expenses
advance payments																																			0	0	-35,000	-92,000	0
net cash from (used) in investing activities
net realized losses (gains) on sales of marketable securities
issuance costs for public offering of common stock in accounts payable and accrued expenses																																	-135,000	328,000
net realized gains on sales of marketable securities																															0
due to related party under services agreement																																							0
other related party payables																																							-349,000
restricted cash																																			0	0
proceeds from issuance of series c convertible preferred stock, net of transaction costs																																							0
proceeds from issuance of series d convertible preferred stock, net of transaction costs																																							0
proceeds from initial public offering of common stock, net of transaction costs
net increase in cash and cash equivalents																															-13,228,000	2,235,000	-24,396,000	57,205,000	-3,268,000	-1,975,000	-5,428,000	-18,605,000	-151,208,000
cash and cash equivalents
cash paid for interest																																							0
conversion of accrued service fees to related party into series c convertible preferred stock
conversion of related party promissory notes into series c convertible preferred stock																																							0
conversion of convertible preferred stock into common stock upon initial public offering																																							0
realized gains on sales of marketable securities																																	0	-480,000
issuance costs for potential public offering of common stock
proceeds from related party promissory notes
deferred issuance costs for potential public offering of common stock in accrued expenses
deferred issuance costs for series c convertible preferred stock in accrued expenses
unrealized foreign currency transaction gains
imputed interest on related party promissory notes																																							0
proceeds from initial public offering of common stock, net of underwriting discounts and commissions
issuance costs for initial public offering
issuance costs for initial public offering in accounts payable and accrued expenses
deferred issuance costs for initial public offering in accrued expenses
unrealized foreign currency transaction losses																																						-13,000
trade receivables																																							-1,542,000
related party receivables																																							0
unbilled receivables																																							0
proceeds from issuance of series b preferred units, net of transaction costs
conversion of accrued service fees to related party into series b preferred units
amortization of premiums on marketable debt securities
accrued expenses
payments of initial public offering costs
conversion of accrued service fees into series c convertible preferred stock
purchases of property and equipment in accounts payable

We provide you with 20 years of cash flow statements for REGENXBIO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of REGENXBIO stock. Explore the full financial landscape of REGENXBIO stock with our expertly curated income statements.

The information provided in this report about REGENXBIO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.